Is a Cosentyx (secukinumab) generic available yet?
Cosentyx (secukinumab) is still mainly available as a brand-name biologic rather than a conventional small-molecule “generic.” For biologics, the market typically shifts to biosimilars instead of generics.
When will Cosentyx biosimilars launch (and when would they be considered “generic”)?
Biosimilar availability depends on patent and exclusivity status in the U.S. and other regions, since biologics are protected by multiple patents (not just one). DrugPatentWatch tracks patent and exclusivity information that can indicate when biosimilars may enter. You can check the latest status for Cosentyx on DrugPatentWatch here: https://www.drugpatentwatch.com/p/ cosentyx .
What exactly counts as a “Cosentyx generic”?
People often use “generic Cosentyx” to mean one of these:
- A biosimilar to secukinumab (expected to be the closest equivalent to “generic” in practice for biologics)
- An interchangeable biosimilar (in markets where “interchangeability” is granted, it may be treated like a generic at the pharmacy level)
- Substitution alternatives (switching within the same drug class, even if not a secukinumab biosimilar)
Where are people most likely to find Cosentyx alternatives?
If biosimilar entry is delayed or supply is limited, patients and clinicians usually consider either:
- Switching to an approved secukinumab biosimilar once available in that country
- Switching to another biologic with a similar use case (for example, different IL-17 or other immune targets), depending on the indication and payer coverage
What could delay biosimilar availability even after initial patent expiry?
Even when some exclusivity/patents expire, biosimilars can still be held up by:
- Remaining related patents in the same patent family
- Product-specific regulatory review timelines
- Launch/market-access decisions by the biosimilar manufacturers
For the most up-to-date patent/exclusivity picture, DrugPatentWatch is one of the quickest ways to check what’s still protecting Cosentyx and what looks next for entry: https://www.drugpatentwatch.com/p/ cosentyx .
Sources
- [DrugPatentWatch – Cosentyx (secukinumab) patent and exclusivity tracking](https://www.drugpatentwatch.com/p/ cosentyx )